COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
United States, Nevada, Las Vegas, DelveInsight’s “Myelofibrosis – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Myelofibrosis market share of the individual therapies, current and forecasted Myelofibrosis market size from 2019 to 2032 segmented by seven major markets. The report also offers current Myelofibrosis therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Myelofibrosis market.
Myelofibrosis Overview
Myelofibrosis is a rare type of blood cancer characterized by the buildup of scar tissue, called “fibrosis,” in the bone marrow. The bone marrow cannot make enough healthy blood cells due to increased scar tissue. It is one of the related groups of blood cancers known as “myeloproliferative neoplasms (MPNs)” in which blood cells produced by bone marrow cells develop and function abnormally. When myelofibrosis develops on its own (and not as the result of another bone marrow disease), it is called primary myelofibrosis. In other cases, another type of MPN, such as polycythemia vera (PV) or essential thrombocythemia (ET), can transform into MF. In these cases, it is known as secondary MF, which may also be referred to as a post-PV MF or post-ET MF.
Myelofibrosis Epidemiological Insights
The total prevalent population of myelofibrosis in the 7MM comprised of approximately 39,700 cases in 2021 and is projected to increase during the study period (2019–2032).
Myelofibrosis Treatment Market
No drug therapy can cure myelofibrosis. The only potential cure for myelofibrosis is allogeneic stem cell transplantation, but this procedure is risky for older patients and those with other health problems. As MF primarily affects older adults, stem cell transplantation is not a treatment option for most MF patients. For most people with myelofibrosis, treatment remains aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival.
For patients with low-risk symptoms, treatment options include Ruxolitinib (Jakafi), Interferon alfa (Intron A, Roferon-A, and Pegasys), although the best use of these medications may be in a clinical trial, and Hydroxyurea (Hydrea).
Patients with Intermediate and high-risk treatment may include Pacritinib (Vonjo), Ruxolitinib (Jakafi), Fedratinib (Inrebic), and allogeneic stem cell transplantation.
Promising Therapies in the Myelofibrosis Pipeline
Discover more about Myelofibrosis therapies in the pipeline @ Myelofibrosis Drugs
Leading Companies Working in the Myelofibrosis Market
To understand key companies related to the Myelofibrosis Market, get a snapshot of the Myelofibrosis Regulatory and Patent Analysis.
Scope of the Myelofibrosis Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Myelofibrosis Companies: Incyte, Novartis, Impact Biomedicines, Celgene, CTI BioPharma, Sierra Oncology, AbbVie, Bristol Myers Squibb, MorphoSys, and others
Key Myelofibrosis Pipeline Therapies: JAKAFI (Ruxolitinib), INREBIC (Fedratinib), VONJO (Pacritinib), Momelotinib, Navitoclax (ABT-263), Parsaclisib (INCB050465), REBLOZYL (Luspatercept/ACE-536), Pelabresib, and others
Therapeutic Assessment: Myelofibrosis current marketed and emerging therapies
Myelofibrosis Market Dynamics: Myelofibrosis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Myelofibrosis Market Access and Reimbursement
Table of Contents
Leading Reports by DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Kritika Rehani
info@delveinsight.com
+1(919)321-6187